Literature DB >> 31653580

Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits.

Yang Tian1, Dianying Liu2, Dongmei Wang1, Jiesi Wang1, Hang Xu1, Qilong Dai1, Elena C Andriescue3, Hanjing E Wu3, Meihong Xiu4, Dachun Chen4, Li Wang1, Yiwen Chen2, Ruilang Yang2, Anshi Wu5, Chang Wei Wei6, Xiangyang Zhang7.   

Abstract

The prevalence of obesity in schizophrenia patients is high, especially in chronic and medicated patients. Few studies have explored the relationships between obesity, cognition and clinical correlates in patients with schizophrenia. This study was designed to assess the prevalence and clinical correlates of obesity and its relationship to cognitive impairment in Chinese patients with schizophrenia. We recruited 633 inpatients and collected clinical, demographic data and lipid parameters. The Positive and Negative Syndrome Scale (PANSS) and its five-factor model were adopted for psychopathological symptoms. The prevalence of comorbid obesity in schizophrenia patients was 16.4%. The plasma levels of glucose, triglyceride, low density lipoprotein (LDL), apolipoprotein B, and cholesterol were higher, but high density lipoprotein (HDL) levels were lower in obese patients than those in non-obese patients (all p < 0.05). Furthermore, obese patients had lower PANSS negative symptom, cognitive factor and total scores than non-obese patients (all p < 0.05). Correlation analysis showed a significant correlation between BMI and the following variables: age, marriage, gender, negative symptoms, general psychopathological symptoms, cognitive factor, PANSS total score, glucose, triglycerides, HDL, LDL, cholesterol and apolipoprotein B (all p < 0.05). Further multiple regression showed that PANSS cognitive factor, PANSS total score, and triglyceride were important independent predictors of obesity. Our results indicate a high prevalence of obesity in Chinese patients with chronic schizophrenia. Multiple demographics, clinical variables, and lipid parameters are associated with obesity in schizophrenia. Moreover, obesity appears to be a protective factor for psychological symptoms. However, not having objective assessments for cognition in this study is a limitation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Body mass index; Clinical symptom; Cognition; Obesity; Schizophrenia

Mesh:

Year:  2019        PMID: 31653580     DOI: 10.1016/j.schres.2019.10.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study.

Authors:  Na Yong; Jiyang Pan; Xuehua Li; Ling Yu; Xin Hou
Journal:  Eur J Med Res       Date:  2022-06-11       Impact factor: 4.981

2.  Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls.

Authors:  Yang Tian; Dongmei Wang; Gaoxia Wei; Jiesi Wang; Huixia Zhou; Hang Xu; Qilong Dai; Meihong Xiu; Dachun Chen; Li Wang; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2020-11-25       Impact factor: 4.530

3.  APOE E4 is associated with hyperlipidemia and obesity in elderly schizophrenic patients.

Authors:  Wei Li; Fengju Liu; Rui Liu; Xinmei Zhou; Guanjun Li; Shifu Xiao
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

4.  Childhood trauma and cardiometabolic risk in severe mental disorders: The mediating role of cognitive control.

Authors:  Synve Hoffart Lunding; Carmen Simonsen; Monica Aas; Linn Rødevand; Maren Caroline Frogner Werner; Jannicke Fjæra Laskemoen; Gabriela Hjell; Petter Andreas Ringen; Trine Vik Lagerberg; Ingrid Melle; Ole A Andreassen; Torill Ueland; Nils Eiel Steen
Journal:  Eur Psychiatry       Date:  2021-03-29       Impact factor: 5.361

5.  Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.

Authors:  Anastasiia S Boiko; Ivan V Pozhidaev; Diana Z Paderina; Anna V Bocharova; Irina A Mednova; Olga Yu Fedorenko; Elena G Kornetova; Anton J M Loonen; Arkadiy V Semke; Nikolay A Bokhan; Svetlana A Ivanova
Journal:  Pharmgenomics Pers Med       Date:  2021-09-07

6.  Sex Differences in Obesity and Cognitive Function in Chinese Elderly Patients With Chronic Schizophrenia.

Authors:  Wei Li; Sun Lin; Ling Yue; Yuan Fang; Shifu Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-01       Impact factor: 6.055

7.  Homocysteine level, body mass index and clinical correlates in Chinese Han patients with schizophrenia.

Authors:  Yuanyuan Huang; Kai Wu; Hehua Li; Jing Zhou; Dongsheng Xiong; Xia Huang; Jiahui Li; Ya Liu; Zhilin Pan; David T Mitchell; Fengchun Wu; Xiang Yang Zhang
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

8.  Prevalence and clinical characteristics of COVID-19 in inpatients with schizophrenia in Wuhan, China.

Authors:  Hong-Wei Sheng; Hong-Gang Wang; Chun-Zhi Wang; Jiang Wu; Li-Jian Huo; Ruo-Xi Wang; Yong-Jie Zhou; Xiang-Yang Zhang
Journal:  World J Psychiatry       Date:  2022-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.